Kailera Therapeutics (NASDAQ:KLRA) Hits New 12-Month Low – Here’s Why

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s share price reached a new 52-week low during trading on Wednesday . The stock traded as low as $17.50 and last traded at $18.41, with a volume of 421803 shares. The stock had previously closed at $17.91.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on KLRA shares. TD Cowen assumed coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $57.00 price target for the company. Leerink Partners assumed coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “outperform” rating and a $36.00 price objective on the stock. Evercore began coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating for the company. JPMorgan Chase & Co. assumed coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 target price for the company. Finally, Zacks Research raised shares of Kailera Therapeutics to a “hold” rating in a report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $42.75.

Kailera Therapeutics Price Performance

The firm has a market capitalization of $2.39 billion and a price-to-earnings ratio of -0.01. The firm has a 50 day moving average of $20.69.

Kailera Therapeutics (NASDAQ:KLRA) last posted its quarterly earnings results on Tuesday, May 26th. The company reported ($3,650.00) earnings per share for the quarter.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.